Jan 08,2018

Glucose monitor maker Intuity Medical brings in $40M

Fremont, California-based Intuity Medical, a diabetes management technology company, announced that it will be receiving $40 million in equity financing from several of its previous investors, including Accuitive Medical Ventures, Investor Growth Captial, KCK Group, affiliates of Luther King Capital Management, PTV Healthcare Capital, US Venture Partners, and Versant Ventures.

FUNDING VENTURE ROUND
View Analyst & Ambassador Comments
Go to original news
Jan 08,2018

Fitbit invests $6M in glucose monitoring startup Sano

Fitbit has recently invested $6 million in San Fransisco-based Sano, a company developing a mobile app and sensor that will allow users to continuously monitor blood glucose levels, multiple publications have confirmed.

FUNDING SERIES A
View Analyst & Ambassador Comments
Go to original news
Jan 11,2018

Study: Online simulator helps diabetes patients understand the impact of exercise on blood glucose

A new app developed by researchers at the University of Utah may be a tool for helping people living with diabetes change their attitude towards physical activity and increase the time they plan to spend exercising. A recent study, published in the Journal of Medical Internet Research, shows that users of this app increased their plans to walk for exercise in the next week by 33.5 minutes.

CLINICAL STUDY

#mobile app

View Analyst & Ambassador Comments
Go to original news
Jan 12,2018

UnitedHealthcare, Dexcom to launch CGM pilot for Medicare Advantage members

UnitedHealthcare and Dexcom announced today at CES in Las Vegas that they will collaborate on a pilot program to provide Dexcom CGMs to UnitedHealthcare Medicare Advantage plan participants.

COLLABORATION PARTNERSHIP

#insurance

#cgm

View Analyst & Ambassador Comments
Go to original news
Jan 17,2018

WellDoc's BlueStar now available on Solera Health's marketplace

Phoenix, Arizona-based Solera Health, a platform which offers a marketplace for chronic disease management programs, and digital therapeutic maker WellDoc announced the partnership today, and said that the partnership aligns both companies' goals to improve the health of those living with chronic disease by enhancing clinical outcomes and overall health.

COLLABORATION PARTNERSHIP

#product & service

#mobile app

#dtx

View Analyst & Ambassador Comments
Go to original news
Jan 25,2018

JDRF backs EOPatch, a tiny, wearable insulin pump

The Juvenile Diabetes Research Foundation (JDRF) has partnered with South Korean medical device company EOFlow to accelerate the development of EOPatch, the company's wearable insulin pump. EOPatch is a wearable, adhesive insulin pump with a handheld touchscreen-enabled controller that closely resembles a smartphone.

COLLABORATION PARTNERSHIP

#institution

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Jan 28,2018

Omada Health to launch largest clinical trial of digital DPP

Omada Health has made plans with the University of Nebraska Medical Center (UNMC) and Wake Forest University to conduct the largest randomized controlled study of a digital diabetes prevention tool. Study participants will be recruited at UNMC, which will also be responsible for data collection and implementation analysis. Wake Forest researchers will head data system management and quality operational reports, while Omada will take charge of the study’s experimental arm and outcome data.

COLLABORATION PARTNERSHIP

#institution

View Analyst & Ambassador Comments
Go to original news
Jan 08,2018

Medicare Part D (Prescription Drug) Plans May Now Cover Omnipod

Insulet Corporation today announced that the Centers for Medicare and Medicaid Services (CMS) has issued guidance clarifying that Medicare Part D Plan Sponsors may provide coverage for products such as the Omnipod System under the Medicare Part D (prescription drug) program.

PRODUCT

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Jan 08,2018

Tandem Diabetes Care Reports Successful Completion of First Pilot Study Using t:slim X2 Insulin Pump with TypeZero Hybrid Closed Loop Technology and Dexcom G6 Integration; Confirms IDCL Multi-site Study Timeline

Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, today reported the successful completion of the first pilot study using a hybrid closed loop system featuring its t:slim X2™ Insulin Pump with embedded algorithms from TypeZero Technologies and integration with Dexcom® G6 Continuous Glucose Monitoring (CGM). This pilot study was the first of three in the National Institute of Health (NIH)-funded International Diabetes Closed Loop (IDCL) Trial using the t:slim X2 Pump running the algorithm directly on the pump. The second study is now moving forward with enrollment at seven clinical sites and is anticipated to begin in the first quarter of 2018. The IDCL Trial is expected to conclude with a pivotal study in 2018, and Tandem plans to use this data in a PMA submission to the U.S. Food and Drug Administration.

PRODUCT

#insulin pump

#cgm

View Analyst & Ambassador Comments
Go to original news
Jan 09,2018

Tandem Diabetes Care Announces Preliminary 2017 Results and Provides 2018 Guidance

Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, today reported select, unaudited and preliminary results for the year and quarter ended December 31, 2017. The Company intends to report its fourth quarter and full year 2017 financial and operating results on Thursday, March 1, 2018 after the markets close. Management intends to host a conference call at 4:30PM Eastern Time (1:30PM Pacific Time) on that day.

View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES